8-K: bioAffinity Technologies Updates on CyPath Lung Growth and R&D

Sentiment:

Other Events


bioAffinity Technologies released a newsletter detailing commercial expansion of its CyPath Lung test, progress in federal healthcare partnerships, and advancements in its asthma/COPD diagnostic and siRNA therapeutic programs.

Capital raiseThe company announced a $4 million raise in a registered direct financing of common stock and concurrent private placement priced at-the-market under Nasdaq rules in October 2026.

Summary

  • bioAffinity Technologies issued a newsletter on November 19, 2026, providing updates on its business developments.
  • The company reported record testing volume for CyPath Lung in October 2026, with test unit sales in Q3 doubling year-to-date over 2025.
  • Physician adoption of CyPath Lung is increasing, evidenced by an 89% rise in ordering physicians and a 48% growth in orders from existing physicians.
  • A nationwide federal healthcare distribution agreement with AvMEDICAL aims to expand access to CyPath Lung across VA medical centers and other federal facilities.
  • The company is developing noninvasive diagnostics for asthma and COPD, utilizing its flow cytometry+AI platform and selected biomarkers.
  • Research is also underway for a potential therapeutic using self-delivering, stabilized siRNA technology to target skin cancer cells.
  • bioAffinity Technologies has secured additional patent protection for its technology in Hong Kong, China, and Japan, strengthening its intellectual property portfolio.
  • The company raised $4 million in a registered direct financing and concurrent private placement in October 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, highlighting commercial progress and strategic expansion, though significant R&D efforts remain distinct from current revenue streams.

Positives

  • CyPath Lung experienced record testing volume in October 2026.
  • CyPath Lung test unit sales in Q3 doubled year-to-date over 2025, with a 109% increase.
  • Ordering physicians for CyPath Lung increased by 89%, and orders from existing physicians grew by 48%.
  • A nationwide federal healthcare distribution agreement with AvMEDICAL was established to expand access to CyPath Lung.
  • Additional patent protection for CyPath Lung and its diagnostic platform has been secured in Hong Kong, China, and Japan.
  • The company successfully raised $4 million in a registered direct financing and concurrent private placement in October 2026.

Negatives

  • The asthma/COPD diagnostic and siRNA therapeutic programs remain in research and development, distinct from the current commercialization of CyPath Lung.
  • Access through the federal healthcare system via the AvMEDICAL agreement does not represent completed sales.

Risks

  • The company's ability to successfully commercialize CyPath Lung.
  • Risks related to the regulatory environment for laboratory developed tests.
  • The company's ability to obtain sufficient financing to fund operations and development.
  • Achieving and sustaining physician adoption, test utilization, and reimbursement for CyPath Lung.
  • Converting distribution access and market interest into orders and revenue.
  • Successfully conducting research and clinical validation and demonstrating safety, efficacy, and clinical utility.
  • Obtaining and maintaining required regulatory authorizations and complying with evolving regulatory requirements.
  • Maintaining laboratory capacity and quality.
  • Executing collaborations and distribution arrangements.
  • Protecting and enforcing intellectual property.
  • Competing effectively.

Future Outlook

The company anticipates an exciting and productive holiday season, continuing to expand the reach and potential of its technologies. Key areas of focus include growing CyPath Lung adoption and utilization, expanding access through federal healthcare channels, advancing research in asthma/COPD diagnostics, and developing siRNA therapeutics for skin cancer.

Management Comments

  • "We look forward to an exciting and productive holiday season at bioAffinity Technologies as we continue to expand the reach and potential of our innovative technologies."
  • "CyPath Lung continues to gain commercial momentum, with growing adoption by physicians and strong year-over-year growth in test volume."
  • "We are also advancing the science behind CyPath Lung, including its potential use in the surveillance of lung cancer survivors, and developing precision diagnostics to characterize lung inflammation in patients with asthma and COPD that may enable physicians to make more informed treatment choices for individual patients."
  • "We also see promising results of our research to advance our therapeutic discoveries using self-delivering, stabilized siRNA technology to investigate whether skin cancer cells can be targeted while preserving healthy cutaneous tissue representing a potentially significant advancement in selective cancer treatment."
  • "Our progress is a testament to the commitment and expertise of the bioAffinity team as we continue advancing innovative solutions to support earlier disease detection, more informed clinical decisions and better patient outcomes."
  • "We are excited about the opportunities ahead and look forward to keeping you informed as we reach new milestones."

Industry Context

StockSavvy.ai notes that bioAffinity Technologies is operating in the highly competitive and rapidly evolving fields of early disease detection and precision diagnostics. The company's focus on lung cancer, asthma, and COPD aligns with significant unmet needs and large market opportunities, as indicated by the projected growth of the asthma/COPD therapeutics market. The expansion into federal healthcare channels, particularly the VA, is a strategic move to tap into a substantial patient population.

Stakeholder Impact

  • Shareholders: Potential for increased company value through commercial growth and R&D advancements, supported by recent capital raise.
  • Physicians: Increased access to diagnostic tools like CyPath Lung for earlier lung cancer detection and potentially more informed treatment choices for respiratory diseases.
  • Patients: Improved access to noninvasive lung cancer testing and potential for better treatment outcomes through advanced diagnostics and therapeutics.
  • Veterans: Expanded access to CyPath Lung through the AvMEDICAL partnership with the VA healthcare system.
  • Employees: Continued focus on innovation and execution by the bioAffinity team.

Next Steps

  • Continue to expand the reach and potential of innovative technologies.
  • Grow CyPath Lung adoption by physicians and increase test volume.
  • Open new opportunities to bring CyPath Lung to more patients through federal healthcare channels.
  • Advance the science behind CyPath Lung, including its potential use in surveillance of lung cancer survivors.
  • Develop precision diagnostics to characterize lung inflammation in patients with asthma and COPD.
  • Investigate the potential of siRNA technology to target skin cancer cells.
  • Continue to advance innovative solutions for earlier disease detection, more informed clinical decisions, and better patient outcomes.

Key Dates

DateDescription
2024-12-31Year ended December 31, 2025 (referenced for Form 10-K)
2025-10-15Positive research results spur development of new test measuring asthma and COPD-related lung inflammation and drug-related receptors (October 13, 2026)
2026-09-30bioAffinity Technologies joins AvMEDICAL in presenting to physicians and U.S. veterans (September 30, 2026)
2026-10-06Announced over 100% growth in CyPath Lung sales through third quarter 2026 (October 6, 2026)
2026-10-08Japan sends notification of intent to issue patent protection for CyPath Lung and AI-built algorithm (October 8, 2026)
2026-10-09Announced $4 million raised in a registered direct financing and concurrent private placement (October 9, 2026)
2026-10-15Chief Medical Officer presents new perspectives on CyPath Lung's use for cancer risk assessment at CHEST 2026 (October 15, 2026)
2026-11-06Continued momentum in CyPath Lung commercialization in third quarter 2026 (November 6, 2026)
2026-11-11Record number of CyPath Lung tests performed in October 2026 (November 11, 2026)
2026-11-19Date of Report (November 19, 2026)

Recommendation

hold

The filing shows positive commercial traction for CyPath Lung and strategic R&D progress. However, the significant portion of the business still in R&D, the need for continued financing, and the inherent risks in commercializing diagnostic tests warrant a cautious 'hold' recommendation until further sustained revenue growth and regulatory milestones are achieved.

Keywords

CyPath Lung, lung cancer, diagnostics, biotechnology, healthcare, pulmonology, oncology, veterans

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.